![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
GlaxoSmithKline Hoffmann-La Roche |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00148915 |
The purpose of this study is to estimate the effect of oral Boniva (ibandronate sodium)taken once monthly versus placebo on bone quality and strength at the hip at one year.
Condition | Intervention | Phase |
Osteoporosis |
Drug: ibandronate |
Phase IV |
MedlinePlus related topics: | Osteoporosis |
ChemIDplus related topics: | Ibandronate sodium Ibandronic acid |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A One Year, Parallel, Placebo-Controlled, Double-Blind, Randomized Study to Assess the Effect of Monthly 150mg Oral Ibandronate Dosing Versus Placebo on Bone Quality and Strength at the Proximal Femur in Women With Osteoporosis |
Enrollment: | 100 |
Study Start Date: | July 2005 |
Ages Eligible for Study: | 55 Years to 80 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
United States, California | |||||
GSK Clinical Trials Call Center | |||||
Upland, California, United States, 91786 | |||||
United States, Colorado | |||||
GSK Clinical Trials Call Center | |||||
Lakewood, Colorado, United States, 80227 | |||||
GSK Clinical Trials Call Center | |||||
Boulder, Colorado, United States, 80304 | |||||
United States, Florida | |||||
GSK Clinical Trials Call Center | |||||
Miami, Florida, United States, 33156 | |||||
GSK Clinical Trials Call Center | |||||
South Miami, Florida, United States, 33143 | |||||
GSK Clinical Trials Call Center | |||||
West Palm Beach, Florida, United States, 33407 | |||||
United States, Georgia | |||||
GSK Clinical Trials Call Center | |||||
Atlanta, Georgia, United States, 30308 | |||||
GSK Clinical Trials Call Center | |||||
Decatur, Georgia, United States, 30033 | |||||
United States, Indiana | |||||
GSK Clinical Trials Call Center | |||||
Indianapolis, Indiana, United States, 46202 | |||||
United States, Maine | |||||
GSK Clinical Trials Call Center | |||||
Bangor, Maine, United States, 04401 | |||||
United States, Maryland | |||||
GSK Clinical Trials Call Center | |||||
Bethesda, Maryland, United States, 20817 | |||||
United States, Michigan | |||||
GSK Clinical Trials Call Center | |||||
Flint, Michigan, United States, 48532 | |||||
United States, Missouri | |||||
GSK Clinical Trials Call Center | |||||
St. Louis, Missouri, United States, 63110 | |||||
United States, New Mexico | |||||
GSK Clinical Trials Call Center | |||||
Albuquerque, New Mexico, United States, 87106 | |||||
United States, New York | |||||
GSK Clinical Trials Call Center | |||||
West Haverstraw, New York, United States, 10993 | |||||
United States, Pennsylvania | |||||
GSK Clinical Trials Call Center | |||||
Duncansville, Pennsylvania, United States, 16635 |
GlaxoSmithKline |
Hoffmann-La Roche |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Study ID Numbers: | BON103593 |
First Received: | September 6, 2005 |
Last Updated: | August 27, 2007 |
ClinicalTrials.gov Identifier: | NCT00148915 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
![]() |